Costello Medical

Pharmaceuticals, Biotechnology and Life Sciences

Targets set1.5°CNet-Zero: Targets set

SBTI ID

40013348

Informations générales

Localisation

United Kingdom

Europe

Secteur d'activité

Pharmaceuticals, Biotechnology and Life Sciences

Type d'organisation

SME

Dernière mise à jour

07/08/2025

Objectifs à court terme (Near-Term)
Engagement de réduction des émissions à horizon FY2030

Statut

Targets set

Classification

1.5°C

Année cible

FY2030

Progression vers l'objectif0%
2015 (année de référence)FY2030
Objectifs à long terme (Long-Term)
Engagement de réduction des émissions à horizon FY2050

Statut

Targets set

Classification

1.5°C

Année cible

FY2050

Progression vers l'objectif0%
2015 (année de référence)FY2050
Description complète des objectifs

This target was approved using a streamlined target validation route exclusive to small and medium-sized enterprises (SMEs). https://docs.sbtiservices.com/resources/FAQsforSMEs.pdf Costello Medical commits to reduce scope 1 and scope 2 GHG emissions 42 % by FY2030 from a FY2023 base year, and to measure and reduce its scope 3 emissions. Costello Medical commits to reach net-zero latest by FY2050. As part of this, it commits to reduce absolute scope 1, 2 and 3 GHG emissions 90% by FY2050 from a FY2022 base year.

Net-Zero

Statut

Targets set

Année cible

FY2050

Progression0%
Classification détaillée

The targets covering greenhouse gas emissions from company operations (scopes 1 and 2) are consistent with reductions required to keep warming to 1.5°C

Source : Science Based Targets initiative | Données publiques